Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 4, Issue 2 (2015)

To study methotrexate and apremilast’s relative effectiveness in treating plaque psoriasis

Author(s):
Dr. Pinninti Srivalli and Dr. Sachin Devendrarao Shende
Abstract:
Introduction and Objectives: Psoriasis is a debilitating skin condition that requires constant attention to keep the condition under control. Constant, long-term usage of the traditional anti-psoriatics may have harmful side effects. The purpose of this study is to decide whether Apremilast, when taken orally, effectively and safely treats moderate to severe plaque psoriasis.
Materials and Methods: Patients with psoriasis undergoing outpatient care at, Department of Dermatology, Maharajah’s Institute of Medical Sciences, Nellimarla, Vizianagaram, Andhra Pradesh, participated in a prospective study. This study was conducted between the February 2014 to March 2015.
Results: This study compares the clinical efficacy of apremilast with methotrexate using the PASI score; it is a randomised trial. The PASI 75 is used to measure the therapy response in this investigation. Reduced from the original PASI score by 75% is PASI 75. Our study found that 34 patients were able to reach the PASI 75. Three patients from Group A and three from Group B were among the six who failed to reach the PASI 75. Two patients in group B failed to make their payments. In our study, 85% of patients were able to fulfil their goal after four months of treatment with methotrexate at a dose of 7.5 mg weekly, divided into three doses 12 hours apart.
Conclusion: When compared to Methotrexate, Apremilast had a worse safety profile and was less effective in treating moderate to severe plaque psoriasis, according to the study.
Pages: 114-117  |  112 Views  48 Downloads


The Pharma Innovation Journal
How to cite this article:
Dr. Pinninti Srivalli, Dr. Sachin Devendrarao Shende. To study methotrexate and apremilast’s relative effectiveness in treating plaque psoriasis. Pharma Innovation 2015;4(2):114-117.

Call for book chapter